Risk Factors for Low Birth-Weight in Areas with Varying Malaria Transmission in Korogwe; Tanzania: Implications for Malaria Control

Low birth weight (LBW) is a risk factor for infant mortality; morbidity; growth retardation; poor cognitive development; and chronic diseases. Maternal exposure to diseases such as malaria; HIV; and syphilis has been shown to have a significant impact on birth weight (BW). This study was aimed at determining whether there was a difference in rates of LBW in areas of varying malaria transmission intensity in Korogwe; Tanzania. Retrospective data for one year (June 2004-May 2005) in three maternal and child health (MCH) clinics in the district were analysed. Villages were stratified into three strata: lowlands-semi urban (average altitude of 320m); lowlands-rural (below 600m) and highlands (=600m). There was a significant decreasing trend of rate of LBW from rural lowlands to highlands (X2 trend =7.335; P=0.007). Adjusting for covariates; women in parity-two were at reduced risk of delivering LBW babies compared to first parity women (OR=0.44; 95CI 0.19-0.98; P=0.045). Similarly; the risk of LBW was higher in women who had delayed MCH gestational booking and in women who conceived during high malaria transmission seasons. There was high degree of preference of digits ending with 0/5 in reporting BW in the studied MCHs. In conclusion; a rate of LWB was high in rural lowlands where malaria is also endemic; and was associated with high malaria transmission seasons

Biological and Haematological Safety Profile of Oral Amodiaquine and Chloroquine in Healthy Volunteers with or without Plasmodium falciparum Infection in Northeast Tanzania

Amodiaquine (AQ); an effective antimalarial drug for uncomplicated malaria; has been greatly restricted after cases of life-threatening agranulocytosis and hepatic toxicity during prophylactic use. We conducted a hospital based open-label randomised clinical trial in 40 indigenous semi-immune healthy adult male volunteers with and without malaria parasites. The objective was to collect data on biological and haematological safety; tolerability; and parasitological efficacy to serve as baseline in the evaluation of the effectiveness of AQ preventive intermittent treatment against malaria morbidity in infants. Volunteers were stratified according to parasitaemia status and randomly assigned 20 participants each arm to three days treatment with either AQ or chloroquine (CQ). The level of difference of selected haematological and hepatological values pre-and post-trial were marginal and within the normal limits. Clinical adverse effects mostly mild and transient were noticed in 33.3CQ treated-aparasitaemic; 23.8of CQ treated-parasitaemic; 28.6of AQ-treated parasitaemic and 14.3of aparasitaemic receiving AQ. Amodiaquine attained 100parasitological clearance rate versus 70in CQ-treated volunteers. The findings indicate that there was no agranulocytosis or hepatic toxicity suggesting that AQ may pose no public health risk in its wide therapeutic dosage uses. Larger studies are needed to exclude rare adverse effects